Pages that link to "Q34608783"
Jump to navigation
Jump to search
The following pages link to Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study (Q34608783):
Displaying 50 items.
- A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin [...] (Q24616813) (← links)
- Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives (Q26747009) (← links)
- Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects (Q26829098) (← links)
- Something old, something new and something very old: drugs for treating type 2 diabetes (Q26865663) (← links)
- Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review (Q26866784) (← links)
- Residual macrovascular risk in 2013: what have we learned? (Q26996039) (← links)
- Role of lipotoxicity in endothelial dysfunction (Q27000731) (← links)
- PPARgamma-Dependent Control of Renin Expression: Molecular Mechanisms and Pathophysiological Relevance (Q27009036) (← links)
- Fibrates, glitazones, and peroxisome proliferator-activated receptors (Q28279732) (← links)
- Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes (Q28730590) (← links)
- PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. (Q30241952) (← links)
- The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis (Q33562214) (← links)
- Minireview: Challenges and opportunities in development of PPAR agonists (Q33631921) (← links)
- Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action (Q33664745) (← links)
- New frontiers in the treatment of diabetic dyslipidemia (Q33776236) (← links)
- Molecular determinants of the cardiometabolic phenotype (Q33921392) (← links)
- Brown fat as a therapy for obesity and diabetes (Q34099153) (← links)
- New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease (Q34398065) (← links)
- Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome (Q34567151) (← links)
- Pharmacological and non-pharmacological interventions to influence adipose tissue function. (Q34576535) (← links)
- Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study (Q34618210) (← links)
- Emerging drugs for hyperlipidemia (Q34619115) (← links)
- Effects of high dose aleglitazar on renal function in patients with type 2 diabetes (Q34623405) (← links)
- Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk (Q34628781) (← links)
- Discontinued in 2013: diabetic drugs (Q34664870) (← links)
- Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer (Q34878637) (← links)
- Impaired lipid metabolism in idiopathic pulmonary alveolar proteinosis (Q34992980) (← links)
- Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? (Q35049058) (← links)
- Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study (Q35189566) (← links)
- A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). (Q35329472) (← links)
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials (Q35581749) (← links)
- Diabetes mellitus: new challenges and innovative therapies (Q36117595) (← links)
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions (Q36261125) (← links)
- Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities (Q36419283) (← links)
- Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases (Q36918509) (← links)
- Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system (Q36952106) (← links)
- Cardiometabolic interventions - focus on transcriptional regulators (Q37161933) (← links)
- Established and emerging approaches for the management of dyslipidaemia (Q37288105) (← links)
- Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. (Q37298699) (← links)
- A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. (Q37556648) (← links)
- Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. (Q37597024) (← links)
- LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. (Q37622614) (← links)
- PPARγ and Its Role in Cardiovascular Diseases. (Q37627571) (← links)
- Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. (Q37702199) (← links)
- Strategies for the development of new PPAR agonists in diabetes (Q37757988) (← links)
- Emergence of promising therapies in diabetes mellitus (Q37779684) (← links)
- Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises (Q37827882) (← links)
- Management of type 2 diabetes: new and future developments in treatment (Q37894446) (← links)
- Immunomodulation using agonists and antagonists: potential clinical applications (Q37965728) (← links)
- New lipid-lowering drugs: an update (Q37984782) (← links)